Wednesday, October 3, 2012

Merck presents data on once weekly DPP-IV inhibitor - MK 3102

The findings reported today are from a multicenter, randomized, double-blind, placebo-controlled dose-ranging study designed to evaluate five doses of MK-3102 (0.25,1, 3, 10 and 25 mg) in patients with type 2 diabetes who had inadequate glycemic control on diet and exercise.A total of 685 patients with a mean baseline HbA1c of approximately 8 percent were
randomized: 571 patients received MK-3102 at one of the five once-weekly doses (0.25 mg, n=113; 1 mg, n=115; 3 mg, n=114; 10 mg, n=115; 25 mg, n=114) and 114 patients received placebo for 12 weeks. The primary endpoint was change in HbA1c from baseline at 12 weeks compared to placebo across doses. The secondary endpoints were 2-hour post-meal glucose and fasting plasma glucose.

Study Results
MK-3102 significantly reduced HbA1c compared to placebo from a mean baseline of approximately 8 percent across all doses. In the full study population at 12 weeks, the placebo-adjusted reduction from baseline in HbA1c was 0.71 percent with MK-3102 25 mg; 0.67 percent with 10 mg; 0.49 percent with 3 mg; 0.50 percent with 1 mg; and 0.28 percent with 0.25 mg.

Post Prandial Glucose Reduction
A statistically significant trend was observed across doses studied for the secondary endpoints of 2-hour post-meal glucose (PMG) and fasting blood glucose (FPG). For 2-hour PMG placebo-adjusted reductions from baseline at week 12 were: MK-
3102 25 mg=2.5 mmol/L; 10 mg=2.3 mmol/L; 3 mg=1.9 mmol/L; 1 mg=1.9 mmol/L; 0.25 mg=1.0 mmol/L.

Fasting Plasma Glucose Reduction
For FPG, placebo-adjusted reductions from baseline at week 12 were MK-3102 25 mg=1.2 mmol/L; 10 mg= 0.7 mmol/L; 3 mg=0.8 mmol/L; 1 mg=1.1 mmol/L; 0.25 mg=0.1 mmol/L.

In the study, MK-3102 was generally well tolerated with a safety profile that was generally similar to placebo

No comments:

Post a Comment